Subcutaneous Rituximab Improves Progression-Free Survival in Low-Tumor Burden Follicular Lymphoma
Researchers sought to determine whether subcutaneous rituximab would improve survival in patients with low-tumor burden follicular lymphoma.
Researchers sought to determine whether subcutaneous rituximab would improve survival in patients with low-tumor burden follicular lymphoma.
The risk of in-hospital death from COVID-19 for patients with cancer differs by sex and cancer type, according to a new study.
Increased risk of intracranial tumors, leukemia, and lymphoma by age 25 seen with exposure to four or more CT scans during childhood.
Researchers sought to determine whether adding crizotinib to chemotherapy would improve responses in pediatric patients with ALCL.
Researchers sought to determine the efficacy of lisocabtagene maraleucel in LBCL compared with standard of care for primary refractory or early relapsed disease.
A bispecific CAR T-cell therapy produced responses in 91% of patients with relapsed/refractory non-Hodgkin lymphoma in a phase 1 trial.
Researchers sought to determine whether tafasitamab would lead to durable responses in patients with R/R DLBCL.
Polivy is a CD79b-directed antibody and microtubule inhibitor conjugate.
Researchers sought to determine the safety and efficacy of sugemalimab in patients with relapsed/refractory extranodal natural killer cell or T-cell lymphoma.
Researchers sought to determine adherence to guidelines for oncologists utilizing PET-adapted strategies for patients with III/IV classic Hodgkin lymphoma.